Biofrontera (NASDAQ:BFRI) Releases Earnings Results, Beats Expectations By $0.05 EPS

Biofrontera (NASDAQ:BFRI) released its quarterly earnings data on Thursday. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05, Zacks reports. Biofrontera had a negative net margin of 25.66% and a negative return on equity of 515.34%.

Here are the key takeaways from Biofrontera’s conference call:

• Q2 revenue rose 33% to $12.0 million, driven by approximately 30% Ameluz unit-volume growth and the 2025 price increase. Gross margin expanded to about 80%, while adjusted EBITDA improved to near breakeven from a $5.1 million loss a year earlier.
• Commercial momentum continued, with first-half order count up 18.6%, average tubes per order up 10%, and the installed base reaching approximately 801 lamps across 740 physician offices. Management said more than 81% of customers that made large pre-price-increase purchases reordered in the first half.
• The ITC exclusion order bars Biofrontera from importing or selling the current RhodoLED XL lamp and restricts Ameluz sales for use with that device. The company is pursuing an appeal and a minor lamp redesign, but must still obtain clearance from border authorities; approximately 243 XL lamps are affected.
• Biofrontera expects potential FDA approval for superficial basal cell carcinoma on September 28, 2026, with a planned first-quarter 2027 launch using its existing lamps and sales force. It also plans to file an expanded actinic keratosis indication by the end of the third quarter and is advancing an acne program toward Phase III.
• Liquidity remains a constraint, with $4.7 million in cash at June 30 and a going-concern qualification in the financial statements. Management expects to reach cash-flow breakeven in 2026 but may need a working-capital facility, while future clinical development depends on available funding.

Biofrontera Price Performance

BFRI stock traded up $0.07 during trading on Thursday, hitting $1.32. The company had a trading volume of 888,010 shares, compared to its average volume of 355,821. The business has a 50 day moving average of $1.07 and a 200 day moving average of $0.98. The firm has a market capitalization of $16.96 million, a price-to-earnings ratio of -1.37 and a beta of 0.78. The company has a current ratio of 1.20, a quick ratio of 1.09 and a debt-to-equity ratio of 0.78. Biofrontera has a fifty-two week low of $0.55 and a fifty-two week high of $1.40.

Institutional Investors Weigh In On Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. boosted its holdings in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 976,448 shares of the company’s stock after acquiring an additional 332,055 shares during the quarter. Biofrontera comprises about 0.3% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 27th biggest holding. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wall Street Zen raised Biofrontera to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold”.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.